Purdue Pharma

The deal, hashed out over weeks of intense negotiations, raises the amount paid by the Sacklers by more than $1 billion. In exchange, the family members win immunity from civil opioid lawsuits.

Nearly half of all U.S. states want a share of a lawsuit settlement with Purdue Pharma to pay for programs to address record overdose deaths and a worsening opioid crisis during the pandemic. We take a look at the impact of the pandemic on addiction treatment and where the recovery community heads from here.

OxyContin maker Purdue Pharma agreed on Monday to pay $4.28 billion to settle lawsuits alleging it helped to create the opioid epidemic.Nearly half of all…

The controversial deal hashed out between the Department of Justice and the maker of Oxycontin provides hundreds of millions of dollars of relief for communities hit hard by the opioid epidemic.

According to a court filing Monday, the family pulled about $10.7 billion from Purdue since 2008 — ramping up withdrawals even after executives pleaded guilty to misleading regulators about OxyContin.

The bankruptcy follows the Sackler family, which owns Purdue, agreeing to surrender control of the company and offering $3 billion in cash to opioid-hit communities.

The pending settlement likely means Purdue will avoid going to trial in the sprawling and complicated case involving some 2,300 local governments across 23 states.

State and local governments suing over the toll of a nationwide opioid crisis agree that companies in the drug industry should be held accountable, but…

Lawsuits over the way drugmakers have marketed opioids are already putting a dent in companies' reputations. Litigation has forced the release of internal documents that are shifting the narrative.

Several drug manufacturers targeted in lawsuits over the opioid epidemic have asked a federal judge in Cleveland to sanction Ohio's attorney general and…